ANBL1821: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed Refractory or Progressive Neuroblastoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 1 - 18 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines, (i.e. > 2 x upper limit of normal [ULN]), at the time of initial diagnosis. 2) Patients must have at least ONE of the following at the time of enrollment: Measurable tumor on magnetic resonance imaging (MRI) or computed tomography (CT) scan.

You may not be eligible for this study if the following are true:

  • 1) Pregnant women. 2) Patients who have received drugs that are strong inducers or inhibitors of CYP3A4 within 7 days prior to study enrollment. 3) Patients with symptoms of congestive heart failure.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.